Inflection Point Biomedical Advisors
Inflection Point Biomedical Advisors provides effective strategic advice and implement hands-on, innovative projects in Precision Medicine for the pharmaceutical and diagnostics industry, investment and VC funds as well as to the EU and US governmental agencies.
IPBA is a key collaborator and vital partner of Article25 Impact Ventures.
Maria Fe Paz
Maria has 20 years experience in healthcare and the biomedical industry, that she leverages to help the healthcare industry, Rx and Dx companies, NGOs, EU/US governments, Investment Funds and Policy Regulators, with strategic biomedical consulting. Prior to founding IPBA, Maria was Chief Medical Officer at Rosetta Genomics and also CMO at Diaceutics, and Founder and President of Labceutics, where she conceptualized and built the global network of labs and contacts. She was the cornerstone to support the definition and implementation of the medical and scientific strategy for the respective teams, and for client’s projects. Maria started her entrepreneurial career in the Precision Medicine field setting up the first private molecular testing laboratories in Spain, nowadays the reference lab Hospital HM Clara Campal labs, that she sold to lead the Global Molecular Medicine Department in Pharmamar (Zeltia) Maria completed her studies at Johns Hopkins in the US, she holds an MD, a PhD as well as an MBA in NGO and Social Services Administration. She is an active member of ASCO, ESMO, AACR and ASEICA. Expert advisor to the European Commission, IMI and OECD, and Board Advisor to The International Cancer Advocacy Network, among other NGOs.
Luiz has academic and professional qualifications in Molecular Biology and over 10 years of experience in the biomarker discovery process. In addition, over the years Luiz has built a relevant track record in strategic market access and development in the biotech/pharma industry, through global product and marketing management. He has been directly responsible for global product launches, pricing, strategy, commercial optimization, KOL network management and training. Luiz’ field of expertise includes molecular assay development and tracking of new technologies/platforms. Prior to IPBA, Luiz was Product Manager and Global Product Marketing Manager at Thermo Fisher Scientific for the Molecular Biology portfolio, including detection technologies; Channel Manager EMEA at Illumina and Global Product Manager IVD at Aesku. During his consulting career, he has been involved and led multiple projects focused on product launch, CDx partnership, testing optimization and market access for different assets, including top 10 drugs.
With over 9 years experience in Life Sciences, Filipa fulfils a key role in IPBA, leading the Market Access strategies of the group and for clients. Before joining IPBA, as a Consultant, she has been responsible for Global Pricing and Market Access for Pharma and Healthcare companies, which includes competitive strategy, global pricing, market access, asset valuation, negotiation strategy and value message testing. During her consulting career, she has also advised companies and governmental agencies (the DG Growth of the European Commission) regarding RDI, investment, internationalization and commercial strategy development. Due to her academic background and work as a researcher, she has an outstanding understanding of Biochemistry, Biophysics and Molecular Biology, as well as a deep scientific knowledge in Cancer Biology and Metabolic Diseases. Filipa holds a PhD in Cancer Molecular Biology from Imperial College London.
From +8 years experiences in major international Research Institutions, managing basic, translational and clinical studies, followed by a position as Product and Application Specialists for all Diagnostics solutions at Dako/Agilent Technologies, Camille developed a strong knowledge and expertise in a wide range of biotechnologies, Cancer Diagnostics/Therapeutics and clinical sciences. He also has extensive hands-on skills and laboratory workflow leadership. Camille holds a PhD in Biotechnologies and Oncology, performed at Institut Curie – France. During its academic period, Camille worked deeply on molecular biology, pre-clinical models, BIG DATAs, medical devices and established secured relationships with KOLs. At Agilent, he engaged in products launching, training, testing optimization, lab workflow studies. He has been also scientific and strategic advisor for Supersonic Imagine on a new market entry project.
With over 10 years of experience in basic and translational research, Giovanni developed an academic background which empowered his broad vision of biomedical and life sciences. He started specializing in advanced basic research applied to early drug screening, later moving to the study of translational pharmacology. The fulfillment of his PhD program in Pharmacology was pursued by conceiving clinical research studies joining the biomedical centers of Bologna Academic hospital S.Orsola-Malpighi and the CURE center, University of California at Los Angeles.
His work experience, envisaging a constant interaction between basic and clinical research was later combined with a focus on the area of Medical Affairs and the cross-functionality of pharmaceutical companies.
With a strong background in biomedical sciences and translational oncology, Jaume has experience in major companies from diagnostics and personalized healthcare landscape. Prior to IPBA, he worked managing medical information at Synlab Global Diagnostics and as Medical Science Liaison of personalized healthcare at Roche, where he acquired a broad knowledge and expertise in cancer biomarkers and diagnostics, cancer therapeutics as well as in diagnostic technologies from extensive areas in the clinical laboratory. He engaged in medical and biomarker trainings, medical events and established close relationships with KOLs. Jaume also holds a MSc in Translational Biomedical Research from Vall d’Hebron Institute of Research, one of the top research institutes in Spain